Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Official title:
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL residual disease.
Primary Purpose: Protocol designed to evaluate remission of disease after treatment discontinuation. Treatment re-started if relapse occurs ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01593254 -
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
|
Phase 2 | |
| Recruiting |
NCT03610971 -
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
|
Phase 2 | |
| Completed |
NCT03045120 -
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
|
||
| Recruiting |
NCT03934372 -
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01702064 -
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
|
Phase 1 | |
| Terminated |
NCT02627677 -
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
|
Phase 3 | |
| Completed |
NCT01660906 -
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
|
Phase 4 | |
| Completed |
NCT01933906 -
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
|
Phase 1 | |
| Completed |
NCT01914484 -
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
|
Phase 1/Phase 2 |